BriaCell Therapeutics Corp (BCTX) concluded trading on Wednesday at a closing price of $2.11, with 6.59 million shares of worth about $13.92 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -78.04% during that period and on July 09, 2025 the price saw a loss of about -27.49%. Currently the company’s common shares owned by public are about 6.56M shares, out of which, 6.34M shares are available for trading.
Stock saw a price change of -26.22% in past 5 days and over the past one month there was a price change of -38.66%. Year-to-date (YTD), BCTX shares are showing a performance of -86.07% which decreased to -75.10% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.76 but also hit the highest price of $29.40 during that period. The average intraday trading volume for BriaCell Therapeutics Corp shares is 1.62 million. The stock is currently trading -30.21% below its 20-day simple moving average (SMA20), while that difference is down -35.99% for SMA50 and it goes to -69.61% lower than SMA200.
BriaCell Therapeutics Corp (NASDAQ: BCTX) currently have 6.56M outstanding shares and institutions hold larger chunk of about 3.67% of that.
The stock has a current market capitalization of $14.31M and its 3Y-monthly beta is at 1.12. It has posted earnings per share of -$8.25 in the same period. It has Quick Ratio of 3.41 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCTX, volatility over the week remained 7.48% while standing at 6.37% over the month.
Analysts are in expectations that BriaCell Therapeutics Corp (BCTX) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 41.56% while it is estimated to increase by 32.70% in next year. EPS is likely to shrink at an annualized rate of 31.60% for next 5-years, compared to annual growth of 47.85% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on February 14, 2022 offering a Buy rating for the stock and assigned a target price of $25 to it.
